secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMMUCELL CORP /DE/ (ICCC)
CIK:        0000811641
Form:       8-K
Filed at:   2022-02-11T23:59:59+00:00
Accession:  0001213900-22-006916
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImmuCell: Dr. Joseph Crabb resigns as officer/employee; remains as consultant for Re-Tain FDA approvals
--------------------------------------------------------------------------------

- Dr. Joseph H. Crabb resigned from all employee and officer roles effective Feb 11, 2022.
- Crabb engaged as consultant/advisor to President; term through April 30, 2023 or FDA approval date.
- Compensation: $70,000 payment due upon receipt of all FDA approvals for Re-Tain (Nisin) if still consulting.
- Payment also triggered by change of control or sale/license of Nisin rights while consulting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/811641/000121390022006916/0001213900-22-006916-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/811641/000121390022006916/ea155463-8k_immucell.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-006916

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer